0001839882-24-007475.txt : 20240311 0001839882-24-007475.hdr.sgml : 20240311 20240311080522 ACCESSION NUMBER: 0001839882-24-007475 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240311 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 24736591 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp_8k-031124.htm CURRENT REPORT
false 0001430306 0001430306 2024-03-11 2024-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): March 11, 2024

 

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

26 Main Street, Chatham New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

  Item 7.01 Regulation FD Disclosure.

 

On March 11, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the presentation of additional efficacy data from the Phase 3 RESILIENT study, the second positive Phase 3 study evaluating the Company’s Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) product candidate for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia. A copy of the press release that discusses this matter is filed as Exhibit 99.01 and hereto and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01Other Events.

 

On March 11, 2024, the Company announced additional efficacy data from the Phase 3 RESILIENT study. The effect sizes of the five continuous key secondary outcomes measures of the study ranged from 0.3 to 0.5. The results demonstrated that Tonmya treatment resulted in an improvement in cognitive dysfunction, measured by the change in the Fibromyalgia Impact Questionnaire-Revised (“FIQ-R”) memory item. The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients versus placebo-treated patients, with a p=0.001 and effect size of 0.31 (LS mean (SE) difference of −0.8 (0.23); nominal p=0.001; effect size 0.31, no correction for multiple comparisons, mixed model repeated measures analysis). The Company believes the activity of Tonmya on pain, sleep quality, fatigue and brain fog are indicative of broad-spectrum activity of Tonmya and suggests that Tonmya treats fibromyalgia at a syndromal level.

 

Forward- Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press Release, dated March 11, 2024

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: March 11, 2024 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE, DATED MARCH 11, 2024
 

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

 

Exhibit 99.01

Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

Phase 3 RESILIENT study of Tonmya met its primary endpoint of daily pain reduction (p=0.00005) and achieved statistically significant improvement on all six key pre-specified secondary endpoints with effect sizes on sleep, fatigue, FIQ-R symptoms and FIQ-R function ranging from 0.3 to 0.5

 

Cognitive dysfunction, or “brain fog,” nominally improved on FIQ-R memory item (p=0.001) where the patients rated their level of memory problems

 

NDA submission expected in the second half of 2024 following pre-NDA meeting with FDA scheduled for the second quarter of 2024

 

CHATHAM, N.J., March 11, 2024 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional efficacy data from RESILIENT, the second positive Phase 3 study evaluating Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024.

 

In presenting more detailed data from the RESILIENT study, Seth Lederman, M.D., President and Chief Executive Officer of Tonix, said, “We previously reported statistically significant and clinically meaningful results in all six key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function. We now report that the effect sizes of the five continuous key secondary outcomes measures ranged from 0.3 to 0.5. The results also showed that Tonmya treatment resulted in an improvement in cognitive dysfunction, or ‘brain fog’, measured by the change in the Fibromyalgia Impact Questionnaire-Revised (FIQ-R) memory item. The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a p=0.001 and effect size of 0.31. Together, we believe the activity of Tonmya on pain, sleep quality, fatigue and brain fog are indicative of broad-spectrum activity of Tonmya and suggest that Tonmya treats fibromyalgia at a syndromal level.”

As previously announced, RESILIENT met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. RELIEF, the first Phase 3 trial of Tonnya 5.6 mg in fibromyalgia, was completed in December 2020. It also met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010). Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 and has scheduled a pre-NDA meeting with FDA in the second quarter of 2024.

Tonmya was not associated with increases in systolic or diastolic blood pressure or body weight, nor were there any reported sexual side effects in the RESILIENT trial. In addition, when systematically investigated using the Changes in Sexual Functioning Questionnaire short form (CSFQ-14), women who received study drug had a higher CSFQ-14 total score relative to those who received placebo, which is consistent with improved sexual function.

 

 
 

 

Dr. Gregory Sullivan, Chief Medical Officer of Tonix Pharmaceuticals said, “These are important tolerability factors for fibromyalgia patients on long-term treatment with the three FDA-approved drugs, since weight gain and fatigue are associated with gabapentinoids, and negative sexual side effects, increased blood pressure and insomnia are associated with SNRIs.”

 

Dr. Lederman added, “We believe that the data from our two positive Phase 3 studies, with clinically meaningful separation from placebo on pain, sleep disturbance, and fatigue, supports the conclusion that fibromyalgia may be successfully treated with Tonmya 5.6 mg, and may provide the opportunity for Tonix to launch the first FDA-approved drug for fibromyalgia in more than a decade. We are excited to bring forward a new first-line treatment to fibromyalgia patients that offers broad symptom relief with favorable tolerability attributes for chronic use and adherence, which provides hope for the 6-12 million affected adults in the U.S.”

 

Dr. Sullivan added, “We believe that these broad-spectrum efficacy results will be important to fibromyalgia patients who struggle not only with pain, but also multiple other symptoms. We also believe the favorable tolerability and side effect profiles will be important to patients and doctors managing this debilitating condition on a long-term basis.”

 

About the Phase 3 RESILIENT Study


The RESILIENT study is a double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of Tonmya (cyclobenzaprine HCl sublingual tablets) in the management of fibromyalgia. The two-arm trial randomized 457 participants in the U.S. across 33 sites. The first two weeks of treatment consist of a run-in period in which participants start on Tonmya 2.8 mg (1 tablet) or placebo. Thereafter, all participants increase their dose to Tonmya 5.6 mg (2 x 2.8 mg tablets) or two placebo tablets for the remaining 12 weeks. The primary endpoint is the daily diary pain severity score change (Tonmya 5.6 mg vs. placebo) from baseline to Week 14 (using the weekly averages of the daily numerical rating scale scores), analyzed by mixed model repeated measures with multiple imputation. The results showed that Tonmya treatment resulted in an improvement in cognitive dysfunction or ‘brain fog’ measured by the change in the FIQ-R memory item. The FIQ-R cognition item showed improvement in Tonmya treated patients vs placebo treated patients (LS mean (SE) difference of −0.8 (0.23); nominal p=0.001; effect size 0.31, no correction for multiple comparisons, mixed model repeated measures analysis). The Cohen’s d effect sizes (ESs) of the five continuous key secondary outcomes measures were: Fibromyalgia Impact Questionnaire-Revised (FIQ-R) – Symptoms domain ES = 0.44, FIQ-R-Function ES =0.30, PROMIS sleep disturbance ES =0.50, PROMIS Fatigue ES = 0.37 and Dairy Sleep quality rating ES = 0.32. The most common adverse events were local administration site reactions that were transient and self-limited.

For more information, see ClinicalTrials.gov Identifier: NCT05273749.

 

 
 

About Fibromyalgia


Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6 million to 12 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

 

About Tonmya* (also known as TNX-102 SL)

 

Tonmya is a centrally acting, non-opioid, non-addictive, bedtime medication. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for the management of fibromyalgia. In December 2023, the company announced highly statistically significant and clinically meaningful topline results in RESILIENT, a second positive Phase 3 clinical trial of Tonmya for the management of fibromyalgia. In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue and improving overall fibromyalgia symptoms and function. RELIEF, the first positive Phase 3 trial of Tonmya in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010) and showed activity in key secondary endpoints.

 

*Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

 

Tonix Pharmaceuticals Holding Corp.*

Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two positive Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase) a biologic designed to treat cocaine intoxication with Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com

 

 
 

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

(919) 360-3039

 

 

 EX-101.SCH 3 tnxp-20240311.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20240311_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20240311_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 11, 2024
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20240311.xsd tnxp-20240311_lab.xml tnxp-20240311_pre.xml tnxp_8k-031124.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp_8k-031124.htm": { "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20240311", "dts": { "schema": { "local": [ "tnxp-20240311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tnxp-20240311_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20240311_pre.xml" ] }, "inline": { "local": [ "tnxp_8k-031124.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp_8k-031124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp_8k-031124.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001839882-24-007475-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-24-007475-xbrl.zip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

XML 16 tnxp_8k-031124_htm.xml IDEA: XBRL DOCUMENT 0001430306 2024-03-11 2024-03-11 iso4217:USD shares iso4217:USD shares false 0001430306 8-K 2024-03-11 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false